Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/46823
Title: Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
Authors: Gurbuz, Mustafa
Kutlu, Yasin
Akkus, Erman
Koksoy, Elif Berna
Kose, Naziyet
Oven, Bala Basak
Uluc, Basak Oyan
Demiray, Atike Gokcen
Erdem, Dilek
Demir, Bilgin
Turhal, Nazim Serdar
Uskent, Necdet
Akbas, Sinem
Selcukbiricik, Fatih
Inal, Ali
Bilici, Ahmet
Olmez, Omer Fatih
Cabuk, Devrim
Unal, Caglar
Hizal, Mutlu
Sendur, Mehmet Ali Nahit
Korkmaz, Mustafa
Karadurmus, Nuri
Erturk, Ismail
Goksu, Sema Sezgin
Tatli, Ali Murat
Guven, Deniz Can
Kilickap, Saadettin
Paksoy, Nail
Aydiner, Adnan
Cinkir, Havva Yesil
Ozkul, Ozlem
Ozturk, Akin
Balli, Sevinc
Kemal, Yasemin
Erdogan, Atike Pinar
Er, Ozlem
Yumuk, Perran Fulden
Demirkazik, Ahmet
Keywords: Atezolizumab
Small cell lung cancer
Immunotherapy
PD-L1
Etoposide
Platinum
Publisher: Springer
Abstract: Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.
URI: https://doi.org/10.1007/s00432-022-04087-x
https://hdl.handle.net/11499/46823
ISSN: 0171-5216
1432-1335
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

6
checked on Dec 14, 2024

WEB OF SCIENCETM
Citations

6
checked on Dec 20, 2024

Page view(s)

66
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.